BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35512453)

  • 1. A mechanistic target of rapamycin inhibitor, everolimus safely ameliorated lupus nephritis in a patient complicated with tuberous sclerosis.
    Okita Y; Yoshimura M; Katada Y; Saeki Y; Ohshima S
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):47-51. PubMed ID: 35512453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus: A case report.
    Koh JS; Oh S; Chung C
    Medicine (Baltimore); 2022 Sep; 101(38):e30554. PubMed ID: 36197220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous sclerosis and fulminant lupus in a young woman.
    Singh N; Birkenbach M; Caza T; Perl A; Cohen PL
    J Clin Rheumatol; 2013 Apr; 19(3):134-7. PubMed ID: 23519178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
    Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 13. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
    Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
    Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coincidence of tuberous sclerosis and systemic lupus erythematosus-a case report.
    Carrasco Cubero C; Bejarano Moguel V; Fernández Gil MÁ; Álvarez Vega JL
    Reumatol Clin; 2016; 12(4):219-22. PubMed ID: 26526985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis.
    Temmoku J; Asano T; Saito K; Matsumoto H; Fujita Y; Furuya-Yashiro M; Matsuoka N; Oda A; Tanabe H; Sato S; Shio-Yano K; Sasajima T; Kiko Y; Kobayashi H; Watanabe H; Shimabukuro M; Migita K
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):41-46. PubMed ID: 34651654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.